Culmination Bio

Culmination Bio is a biotechnology company that has developed a disease-agnostic patient data intelligence platform. The company maintains exclusive rights to a vast cloud-based data lake comprising over 40 years of de-identified patient electronic health records and biospecimen data through its partnership with Intermountain Health. This extensive repository, with over 5 million de-identified patient samples and data spanning several decades, enables biopharmaceutical companies to gain crucial insights for advancing diagnostic and therapeutic development.

Culmination Bio's platform leverages its unique ability to build retrospective and prospective deidentified multi-modal datasets in a disease-specific fashion. This empowers researchers to rapidly access longitudinal patient data, streamlining clinical trial recruitment and accelerating drug discovery efforts. The company's data assets have contributed to significant discoveries, including identifying genes linked to vertigo, migraines, and blood clotting disorders, published in peer-reviewed journals.

Culmination Bio's proprietary Intelligence Platform and querying capabilities allow customers to efficiently retrieve data tailored to their research needs while maintaining patient privacy and regulatory compliance. The company's approach mitigates the risks associated with integrating non-uniform data from multiple sources, providing a one-stop solution for accessing consistent, high-quality patient data and biospecimens.

Key customers and partnerships

In January 2024, Culmination Bio partnered with Merck to support the pharmaceutical giant's autoimmune disease research. The collaboration highlights Culmination Bio's ability to provide rapid access to high-quality longitudinal patient data spanning decades.

Culmination Bio has also collaborated with BillionToOne, a diagnostics company developing liquid biopsy tests in oncology. The partnership aims to validate BillionToOne's Northstar Select and Northstar Response oncology diagnostic tests, leveraging Culmination Bio's extensive data set, including longitudinal patient clinical data and matched biospecimens.

Additionally, Culmination Bio has entered into agreements with several pharmaceutical companies and numerous biotech firms to provide access to its data repository, accelerating their research and development efforts across various therapeutic areas.